PLARIUM
Plarium, a leading developer of mobile, social, and web-based games with more than 290 million players worldwide, is proud to announce the launch of its latest genre-defining casual adventure title, Undersea Solitaire Tripeaks , on Android and iOS. This story-driven game offers the excitement of Solitaire Tripeaks immersed in an engrossing narrative blended with item collection and town-designing features.
The game takes place in the typically idyllic undersea town of Rocky Bottom which has been blown to pieces by a nasty whirlpool. Players must earn gems through their sweet solitaire skills to help Alfred the Crab and his fishy friends rebuild the town and make it bigger than ever before! Along the journey, players will uncover ancient artifacts, host fashion shows, welcome new residents, solve crimes, and much more.
“Plarium has been developing narrative-driven games in the strategy and RPG genres for many years, and we see a strong demand from our casual audiences for the same type of experience,” says Oleg Yakovlev, game producer at Plarium. “This is why we focused on building the first game to blend Solitaire mechanics, a narrative-driven metagame, and town customization gameplay to give players a new challenge unlike anything they have seen before in this genre!”
Undersea Solitaire Tripeaks features 30+ animated 3D characters and over 2000 intricately designed levels with a variety of gameplay mechanics to keep players engaged and entertained. Key gameplay elements include:
- The most ‘blockers’ and ‘boosters’ of any solitaire game: Undersea Solitaire Tripeaks has 15+ unique blockers and 6 boosters to offer players endless challenges.
- 600+ exciting story quests: Players will work alongside a diverse cast of characters to help grow Rocky Bottom into a bustling place with a circus, amphitheater, theme park, and more.
- Epic Challenges Every Day of the Week: Undersea Solitaire Tripeaks features a host of special Solitaire events, daily missions, and much more.
- Thousands of town customization options: Players can rebuild Rocky Bottom just the way they want.
Undersea Solitaire Tripeaks is now available for users worldwide in English, French, German, Italian, Japanese, Korean, Russian, Spanish, Turkish, Traditional Chinese, Simplified Chinese, and Portuguese. It can be accessed through the App Store and Google Play .
About Plarium
Founded in 2009, Plarium Global Ltd. is dedicated to creating the best mobile and social experience for hardcore and casual gamers worldwide. With over 290 million registered users, we're proud to be consistently ranked among Facebook’s top hardcore game developers. Plarium employs more than 1400 individuals and is headquartered in Israel with eight offices and development studios across Europe and the United States. Our games are available on iOS, Android, and Plarium Play, as well as all major social networks, including Facebook, VKontakte, Odnoklassniki and Mail.ru and web browsers. Plarium was acquired by Aristocrat in October 2017 and operates as a wholly owned subsidiary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom